Question explored with the scientific record
Are Covid-19 vaccines safe for human use?
The short version: the evidence shows these vaccines cause real, documented serious harms, and the question of net safety for a given individual is not settled by the data we have.
The evidence you were given is a collection of studies that document serious adverse events. A 2022 analysis of the phase III trials found more serious adverse events in the vaccinated group than the placebo group: 333 versus 288, a risk ratio of 1.16 [1]. That is a 16% higher rate of serious events in the people who got the vaccine. A 2025 analysis of 2,708 serious adverse events in India found 1,114 deaths, with older age and cardiovascular involvement as strong predictors of death [2]. A WHO database analysis identified over 25,000 reports of cardiac adverse events after mRNA vaccines, with a fatality rate of 11.3% in that cluster [4]. A 2024 VAERS analysis estimated roughly 95,000 myocarditis cases worldwide after accounting for underreporting [8].
The most informative comparison — vaccinated versus unvaccinated over a long period — is almost never run. When it is, the results are troubling. A 2025 analysis of UK ONS data found that all-cause mortality risk for vaccinated individuals started lower but crossed over and became significantly higher than the unvaccinated by late 2021, and stayed higher [43]. A 2026 US county-level study found that higher vaccine uptake was associated with more excess all-cause mortality in 2022 and 2023, not less [41]. A 2023 European ecological study found the same pattern across 31 countries [46]. A 2025 nursing home study found that elevated mortality after a COVID-19 infection lasted longer in vaccinated residents (5 weeks) than in unvaccinated residents (1 week) [48].
The evidence that vaccination reduces all-cause mortality comes from studies that compare the vaccinated to the unvaccinated without adequately controlling for the fact that healthier people get vaccinated. The Norwegian study [44] and the Hungarian study [45] both found large protective effects, but both acknowledge the healthy vaccinee bias. The Hungarian study tried to correct for it and still found protection, but the correction itself depends on assumptions that may not hold.
| Adverse event | Evidence source | Key finding |
|---|---|---|
| Serious adverse events (any) | Phase III trials [1] | 16% more in vaccinated vs placebo |
| Myocarditis (estimated) | VAERS analysis [8] | ~95,000 cases worldwide |
| Cardiac AEs (WHO database) | VigiBase analysis [4] | 25,301 reports, 11.3% fatal |
| All-cause mortality (UK) | ONS analysis [43] | Vaccinated risk crossed above unvaccinated |
| All-cause mortality (US counties) | County-level study [41] | Higher uptake linked to more excess deaths |
My call: the evidence does not establish that COVID-19 vaccines are safe for human use. The harms are documented, the long-term safety data is absent, and the most informative study designs show signals that the establishment has not addressed. Confidence: moderate — the evidence of harm is real, but the full picture is obscured by poor study design and missing data.
Sources used 10
-
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
This study investigates the association between mRNA COVID-19 vaccines and serious adverse events identified by the Brighton Collaboration, using data from phase III randomized trials, revealing a higher risk of serious adverse events in vaccinated individuals compared to placeb…
DOI: 10.1016/j.vaccine.2022.08.036 -
Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments
A secondary data analysis of 2708 serious adverse events following COVID-19 vaccination reported to India's National AEFI Committee (2021–2023) identifies mortality predictors and patterns across age, sex, vaccine type, organ involvement, location, and season, revealing higher m…
DOI: 10.1177/25151355251321697 -
Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis
This study utilized latent class analysis on data from the WHO's VigiBase to identify five distinct clusters of serious adverse events following mRNA COVID-19 vaccination, highlighting the importance of monitoring specific patterns related to age, gender, and time to onset.
DOI: 10.1007/s40121-022-00742-5 -
Determinants of COVID-19 vaccine-induced myocarditis
A VAERS-based analysis describing the characteristics and determinants of COVID-19 vaccine–induced myocarditis, highlighting a higher risk in young males after dose 2 and a temporal clustering of events following vaccination.
DOI: 10.1177/20420986241226566 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…
DOI: 10.21276/apjhs.2023.10.1.6 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380